Allergy Immunotherapy Market Analysis

Allergy Immunotherapy Market Analysis

To get key market trends

  Download Free Sample

Based on treatment type, the market is bifurcated into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The sublingual immunotherapy segment is further distinguished into tablets and drops. The subcutaneous immunotherapy (SCIT) segment dominated the market in 2023 and accounted for USD 1.1 billion.
 

• Subcutaneous immunotherapy has been administered for several years. Hence, its efficacy in treating varied allergic conditions has been well studied, making the majority of healthcare providers familiar with this type of treatment.
   
• SCIT targets a wide range of allergens, including dust mites, pollens, insect venom, etc. This broad applicability makes SCIT a versatile option for patients suffering from multiple allergic conditions.
   
• Further, SCIT is said to induce a stronger immune response, making it the first line of preference in severe cases such as venom-induced anaphylaxis. According to Allergy, Asthma & Clinical Immunology, there are nearly 50 to 112 incidences of anaphylaxis per 100,000 people globally, requiring SCIT administration.
   
• Thus, the familiarity of healthcare professionals with SCIT, coupled with the strong immune response delivered by this treatment, will drive the market over the coming years.
   

Based on allergy type, the allergy immunotherapy market is bifurcated into allergic rhinitis, asthma, skin allergy, food allergy, and other allergies. The allergic rhinitis segment dominated the market in 2023 with a market share of 35.1%.
 

• Allergic rhinitis is an allergic condition characterized by inflammation of the nasal passages in response to allergens.
   
• The high prevalence of allergic rhinitis is the primary reason for the substantial market share of this segment. As per the National Institutes of Health, allergic rhinitis affects around 20% to 30% of people in the U.S. and Europe.
   
• Additionally, increasing awareness about allergy immunotherapies, combined with significant diagnosis rates, has driven the demand for immunotherapies for the treatment of allergies.
   

Based on distribution channel, the allergy immunotherapy market is categorized into hospital, retail, and online pharmacies. The hospital pharmacy segment is anticipated to reach USD 2.1 billion by 2032.
 

• Hospital pharmacies play a vital role in managing and dispensing specialized medications, such as allergy immunotherapy, which are essential for treating various allergic conditions.
   
• Additionally, hospitals often serve as primary sites for clinical trials and new drug introductions, facilitating the rapid adoption and utilization of these treatments.
   
• Further, hospital pharmacies work closely with allergists and immunologists to ensure that patients receive the appropriate formulation and dosage of their immunotherapy treatments. This coordination is essential for managing complex cases, including multiple allergies or severe allergic reactions.
   

North America dominated the global allergy immunotherapy market in 2023 with a revenue of USD 780.5 million and is anticipated to reach USD 1.6 billion by 2032.
 

• The region's dominance is attributed to the high prevalence of allergy conditions. According to The Asthma and Allergy Foundation of America  (AAFA), over 100 million people in the U.S. suffer from different types of allergies each year.
   
• Additionally, North America's well-developed healthcare system with high accessibility to specialized care and favorable regulatory pathways facilitates rapid market entry and adoption of new treatments.
   
• The region's high patient awareness and favorable reimbursement policies further contribute to its leading position in the market.
   

The U.S. allergy immunotherapy market was valued at USD 718.9 million in 2023.
 

• The country’s well-developed healthcare infrastructure, high prevalence of allergies, and strong emphasis on research and development contribute to its leading position.
   
• Additionally, the robust healthcare reimbursement system in the U.S. facilitates access to these treatments, further boosting their adoption.
   
• The combination of these elements ensures that the U.S. remains a dominant player in the market, driving both market growth and advancements in treatment.
   

Germany is anticipated to witness robust growth in the global allergy immunotherapy market.
 

• The increasing prevalence of allergies has accelerated the demand for effective immunotherapies in Germany. For instance, according to the National Institutes of Health (NIH), nearly 12.3 million people in the country suffer from allergic rhinitis.
   
• Germany is one of the pioneers in advanced healthcare and pharmaceutical research. Its robust healthcare infrastructure and significant investment in medical innovation provide a strong foundation for market expansion.
   
• Additionally, allergy immunotherapy is often covered under statutory health insurance, making it more accessible and affordable to patients.
   
• The presence of leading pharmaceutical companies and research institutions further stimulates Germany's position as a significant player in the market.
   

The Asia Pacific region is anticipated to witness high growth in the allergy immunotherapy market, growing at a CAGR of 8.8% over the analysis years.
 

• Rapid modernization and elevated levels of air pollution have contributed significantly to rising allergy rates in the region. According to the Global Asthma Report 2022 by the Global Asthma Network, nearly 35 million people in India suffer from asthma, indicating a high necessity for effective treatment.
   
• Additionally, significant investment in healthcare infrastructure development to offer specialized treatments, such as allergy immunotherapy, will positively drive market growth in the region.
   
• Moreover, growing patient awareness, advancements in SLIT, and increasing healthcare expenditure will further drive the market over the projected timeframe.